You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical Vector for TCR Immunotherapy Targeted to Melanoma

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase II proposal is a continuation of our Phase I award, Lentiviral Vectors for TCR Immunotherapy Targeted to Melanoma. We have successfully achieved the milestones laid out in our initial application. We generated a lentiviral gene vector capable of expressing a T cell receptor (TCR) specific for the tyrosinase:368-376 epitope, and demonstrated the act ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. VGo-Assist, A Mobile Telepresence Robot to Engage Persons with Alzheimer's Disease and Related Dementias

    SBC: VECNA TECHNOLOGIES, INC            Topic: NIA

    Project Summary/Abstract Assistive Technologies (AT) is a broad area of activities to support physical health, well-being, social connectedness, and ability to live independently at home. Assistive Robotics (AR) has largely referred to robots that assisted people through physical interaction, while Socially Interactive Robotics (SIR) describe machines that interact primarily through social interac ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. ARPA-H-01 TOPIC: STREPAPP: DEEP LEARNING TO DIAGNOSE STREPTOCOCCAL PHARYNGITIS

    SBC: AUSCULTECH DX LLC            Topic: AH01

    This Phase II project is for the advancement of diagnostic capabilities for detecting Group A Streptococcus pharyngitis (GAS). The goals under the contract include a comprehensive and diverse database, multiple trained and optimized deep learning models deployable on a mobile device, FDA clearance for the algorithms, and the validation of the app's performance through clinical research. These achi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of VLP vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Respiratory syncytial virus (RSV) is a significant human pathogen severely impacting neonates and young children, but no vaccine exists to protect this vulnerable population. Furthermore, direct vaccination of neonates is likely ineffective due to the immaturity of their immune system, and neonate immunization is potentially unsafe. The current view is that maternal vaccination is the best and saf ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NINDS

    Abstract Vamorolone is a first-in-class dissociative steroidal drug that is being developed for Duchenne muscular dystrophy as a replacement for corticosteroid standard of care (prednisone, deflazacort) by small business ReveraGen BioPharma. ReveraGen completed first-in-patient studies with the aid of a NINDS SBIR Direct-to- Phase II award (48 DMD boys; sequential clinical trials VBP15-002, VBP15- ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a number of developed countries, the risk of death associated with HIV-1 infection has sharply declined due to the use of highly active antiretroviral therapy (HAART). Unfortunately, the rate of new HIV i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Pivotal trial of vamorolone in Duchenne muscular dystrophy

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NINDS

    Abstract ReveraGen BioPharma is a clinical stage drug development company that is developing vamoroloneVBPa first in class dissociative steroidal drugThe initial indication being tested is Duchenne muscular dystrophyDMDwhere vamorolone holds promise for retaining or increasing efficacy of glucocorticoidswhile reducing adverse effectsbone fragilitystunting of growthweight gaininsulin resistanceReve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Portable Ankle Robotics to Reverse Foot Drop After Stroke.

    SBC: NEXTSTEP ROBOTICS, INC.            Topic: 105

    This proposal finalizes the design of a portable ankle robot as a therapeutic device to reverse foot drop and restore safer independent walking after stroke, then conducts a rigorous randomized clinical trial to establish clinical proof for this new market application. Currently, there are no therapeutic solutions for foot-drop, only assistive devices (braces, canes, electrical stimulation) that d ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The development of Sanaria's aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoite (SPZ)-based products has received international recognition during the past year, due principally to four findings: 1)PfSPZ Challenge (infectious PfSPZ) induced malaria in volunteers, 2) PfSPZ Vaccine (radiation attenuated PfSPZ) induced unprecedented levels ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government